I wanted to share with you TargetMol Compound Librarys.
Clinical Compound Library:
Clinical compound library is a collection of 1487 compounds, all of which have been permitted into the clinical trial phases. These compounds have known biological activities, low toxicity, and clear mechanism with demonstrated pre-clinical evidence.
Every compound contains detailed information on pharmacological activities, targets, clinical development status, and indications with broad spectrum covering several therapeutic areas from cancer, inflammation, infection, neuropsychiatry to cardiology, and many drug targets such as JAK, EGFR, mTOR, CDK, HDAC, AKT, PARP, etc.
Preclinical Compound Library:
Preclinical Compound Library is a collection of 450 compounds that are in preclinical phase with clear targets and detailed information on disease indication and reference.
Anti-cancer Clinical Compound Library:
We carefully select 594 anti-cancer compounds currently in clinical trial phases based on published literatures and database to form this collection that can be used for high throughput screening and high content screening.
Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of ‘old’ drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compounds, with potentially lower overall development costs and shorter development timelines.
Thanks and look forward to hearing from you.